Previous studies have found that macrophage and T-cell CD4 memory activation in the LUAD immunological landscape is relatively upregulated in patients with LUAD TP53 mutations, potentially playing a role in the suppression of cancer metastasis and the benefit of patient immunotherapy [51]. This evidence concerns the gene TP53 and cancer.